This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Cancer Research Technology Limited. Active years: 2021-2023.
Company Filing History:
Years Active: 2021-2023
Title: Mathew L Calder: Innovator in Cancer Research
Introduction
Mathew L Calder is a prominent inventor based in Cambridge, GB. He has made significant contributions to the field of cancer research through his innovative work and patented inventions. With a total of 2 patents, Calder is recognized for his advancements in pharmaceutical compositions aimed at treating proliferative disorders.
Latest Patents
Calder's latest patents focus on pyrimidinone derivatives as inhibitors of the cell division cycle 7 (Cdc7) kinase enzyme activity. These compounds, defined by specific formulas, are designed to function as inhibitors that can potentially treat various proliferative disorders, including cancer. The inventions also encompass pharmaceutical compositions that utilize these compounds, highlighting their importance in addressing diseases where Cdc7 kinase activity plays a critical role.
Career Highlights
Calder is associated with Cancer Research Technology Limited, where he applies his expertise in developing innovative solutions for cancer treatment. His work is pivotal in advancing the understanding and treatment of cancer through targeted therapies.
Collaborations
Calder collaborates with notable colleagues, including Gregory R Ott and Emma Louise Carswell, contributing to a dynamic research environment focused on cancer innovation.
Conclusion
Mathew L Calder's contributions to cancer research through his patented inventions underscore his role as a key innovator in the field. His work continues to pave the way for new therapeutic approaches in the fight against cancer.